Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study.

IF 5.3 3区 医学 Q1 INFECTIOUS DISEASES
Infectious Diseases and Therapy Pub Date : 2026-05-01 Epub Date: 2026-03-22 DOI:10.1007/s40121-026-01334-3
Karam Mounzer, Michael D Osterman, Laurence Brunet, Ricky K Hsu, Anthony M Mills, Gerald Pierone, Michael G Sension, Jennifer S Fusco, Sean P Fleming, Girish Prajapati, Gregory P Fusco
{"title":"Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study.","authors":"Karam Mounzer, Michael D Osterman, Laurence Brunet, Ricky K Hsu, Anthony M Mills, Gerald Pierone, Michael G Sension, Jennifer S Fusco, Sean P Fleming, Girish Prajapati, Gregory P Fusco","doi":"10.1007/s40121-026-01334-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Although antiretroviral therapy (ART) has substantially improved treatment-related outcomes among people with HIV (PWH), individuals may still undergo ART regimen switches for clinical and non-clinical reasons. While prior studies have focused on virologic outcomes, contemporary data describing ART regimen switching in routine care in the US, especially among virologically suppressed PWH, are limited. In an evolving HIV treatment landscape, including expanding switch strategies, this study estimated the incidence of ART regimen switching among virologically suppressed PWH and characterized switch patterns.</p><p><strong>Methods: </strong>This observational cohort study used prospectively collected, routine electronic health records data from the OPERA Cohort. Adult PWH who were active in care and on a complete ART regimen between July 1, 2024 and June 30, 2025 were eligible. An ART regimen switch was defined as any change in antiretroviral agent, excluding pharmacokinetic boosting agents. Incidence of ART regimen switching was assessed during this 1-year period, overall and among PWH who were virologically suppressed. PWH who underwent a switch were characterized. Pre- and post-suppressed switch regimens, as well as patterns of suppressed switching, were outlined.</p><p><strong>Results: </strong>Among 73,078 PWH who were eligible, 8188 (11%) experienced ≥ 1 ART regimen switch during the 1-year study period. Of 68,147 individuals who were virologically suppressed to < 200 copies/ml during the study period, 6888 (10%) experienced ≥ 1 ART regimen switch while suppressed. The rate of suppressed switching was 14.5 per 100 person-years. Integrase inhibitors predominated both pre- and post-switch regimens. Overall, 51% of suppressed switches resulted in regimen simplification (lower pill count, fewer anchor agents, and/or transition to a complete long-acting injectable regimen).</p><p><strong>Conclusions: </strong>In this large, contemporary US cohort, ART regimen switching was somewhat common and most frequently occurred among virologically suppressed PWH. These real-world findings on the incidence and patterns of virologically suppressed switches provide insight into new trends in treatment optimization and the need for new therapeutic options.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"1297-1314"},"PeriodicalIF":5.3000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129161/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-026-01334-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Although antiretroviral therapy (ART) has substantially improved treatment-related outcomes among people with HIV (PWH), individuals may still undergo ART regimen switches for clinical and non-clinical reasons. While prior studies have focused on virologic outcomes, contemporary data describing ART regimen switching in routine care in the US, especially among virologically suppressed PWH, are limited. In an evolving HIV treatment landscape, including expanding switch strategies, this study estimated the incidence of ART regimen switching among virologically suppressed PWH and characterized switch patterns.

Methods: This observational cohort study used prospectively collected, routine electronic health records data from the OPERA Cohort. Adult PWH who were active in care and on a complete ART regimen between July 1, 2024 and June 30, 2025 were eligible. An ART regimen switch was defined as any change in antiretroviral agent, excluding pharmacokinetic boosting agents. Incidence of ART regimen switching was assessed during this 1-year period, overall and among PWH who were virologically suppressed. PWH who underwent a switch were characterized. Pre- and post-suppressed switch regimens, as well as patterns of suppressed switching, were outlined.

Results: Among 73,078 PWH who were eligible, 8188 (11%) experienced ≥ 1 ART regimen switch during the 1-year study period. Of 68,147 individuals who were virologically suppressed to < 200 copies/ml during the study period, 6888 (10%) experienced ≥ 1 ART regimen switch while suppressed. The rate of suppressed switching was 14.5 per 100 person-years. Integrase inhibitors predominated both pre- and post-switch regimens. Overall, 51% of suppressed switches resulted in regimen simplification (lower pill count, fewer anchor agents, and/or transition to a complete long-acting injectable regimen).

Conclusions: In this large, contemporary US cohort, ART regimen switching was somewhat common and most frequently occurred among virologically suppressed PWH. These real-world findings on the incidence and patterns of virologically suppressed switches provide insight into new trends in treatment optimization and the need for new therapeutic options.

在美国,尽管有病毒学抑制,艾滋病毒感染者中抗逆转录病毒治疗的转换并不罕见:一项OPERA队列研究。
导读:尽管抗逆转录病毒治疗(ART)大大改善了HIV感染者(PWH)的治疗相关结果,但个体仍可能因临床和非临床原因而接受抗逆转录病毒治疗方案的转换。虽然先前的研究集中在病毒学结果上,但描述美国常规护理中ART方案转换的当代数据,特别是病毒学抑制的PWH,是有限的。在不断发展的HIV治疗环境中,包括扩展的切换策略,本研究估计了病毒学抑制的PWH中ART方案切换的发生率和特征切换模式。方法:这项观察性队列研究使用了OPERA队列前瞻性收集的常规电子健康记录数据。在2024年7月1日至2025年6月30日期间积极接受护理和完整ART方案的成年PWH符合条件。ART方案转换定义为抗逆转录病毒药物的任何改变,不包括药代动力学增强剂。在这1年期间,评估了总体和病毒学抑制的PWH患者ART方案转换的发生率。对接受转换的PWH进行了特征描述。概述了前抑制和后抑制开关方案,以及抑制开关的模式。结果:在73078名符合条件的PWH中,8188名(11%)在1年的研究期间经历了≥1次ART方案转换。68147例病毒学抑制个体得出结论:在这个大型的当代美国队列中,抗逆转录病毒治疗方案切换比较常见,并且最常发生在病毒学抑制的PWH中。这些关于病毒学抑制开关的发生率和模式的现实世界发现,为治疗优化的新趋势和对新治疗选择的需求提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infectious Diseases and Therapy
Infectious Diseases and Therapy Medicine-Microbiology (medical)
CiteScore
8.60
自引率
1.90%
发文量
136
审稿时长
6 weeks
期刊介绍: Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书